Kim et al. [90] reported that the disease control rate was 48.5% in the patients with R/R high CD30-expressing NHL including PTCL-NOS (24.2%), ENKTL (21.2%) and AITL (3%). This evidence concerns the gene TNFRSF8 and non-Hodgkin lymphoma.